Hubei Biocause Pharmaceutical Co., Ltd. operates in the Life insurance sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hubei Biocause Pharmaceutical Co., Ltd. with three other
insurance companies in Asia:
Korean Reinsurance Company
of South Korea
(2017
sales of 9.01 trillion Korean Won [US$8.00 billion]
),
China Life Insurance Company Limited
of Taiwan
(268.23 billion Taiwanese Dollars [US$8.70 billion]
of which 100%
was Insurance & Related Activities), and
Mercuries & Associates Investment Ltd
which is
also
based in Taiwan
(215.56 billion Taiwanese Dollars [US$6.99 billion]
of which 86%
was Life Insurance).
Sales Analysis.
Sales increased substantially in 2017:
Hubei Biocause Pharmaceutical Co., Ltd. reported sales of 53.41 billion Chinese Renmimbi (US$7.90 billion)
for the
year ending
December of 2017.
This
represents
an
increase of 214.3%
versus 2016, when the company's sales were 16.99 billion Chinese Renmimbi.
Sales of Insurance saw an increase
of
408.4% in 2017, from
9.23 billion Chinese Renmimbi to 46.91 billion Chinese Renmimbi.